<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03032042</url>
  </required_header>
  <id_info>
    <org_study_id>17-0101</org_study_id>
    <nct_id>NCT03032042</nct_id>
  </id_info>
  <brief_title>Intestinal Microbiome Post-Azythromycin/Albendazole Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francis I. Proctor Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Francis I. Proctor Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Molecular testing of the gut microbiome and enteric pathogens is rapidly moving beyond
      targeted PCR testing to next generation sequencing techniques. In addition, the current state
      of monitoring for soil-transmitted helminth infections is moving increasingly from
      microscopic techniques to molecular techniques. The targeted PCR test for soil transmitted
      helminth diagnosis has been validated on stool samples, but not rectal swabs. Bulk stool
      samples are logistically challenging and time-intensive to collect, thus participation is
      often far from optimal. Rectal swabs are more efficient and may result in higher
      participation. In this study, children will be randomized to either albendazole,
      azithromycin, or both drugs, after which both rectal swabs and bulk stool samples will be
      collected. The investigators will compare the PCR test for soil transmitted helminth
      infections using both the rectal swabs and the bulk stool samples. In addition, the
      investigators will analyze the gut microbiome of the children using next generation
      sequencing techniques to gain insight into effects of mass drug administration.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbial diversity in the intestinal microbiomes of children aged 1-60 months</measure>
    <time_frame>Day 7</time_frame>
    <description>Microbiota diversity in the intestinal microbiomes of children aged 1-60 months in azithromycin-treated, albendazole-treated, azithromycin+albendazole-treated and delayed treatment arms using phylogenetic distance measures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of Soil-transmitted helminth infection detection in rectal swab versus bulk stool sample in children 0-5</measure>
    <time_frame>Day 7</time_frame>
    <description>The investigators use PCR to identify soil transmitted helming infections in rectal swab samples and bulk stool sample from the same child. Using the bulk stool sample as the gold standard, the investigators will calculate the sensitivity, specificity, PPV, and NPV of the rectal swabs for detecting the various helminth infections.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Helminth Infection</condition>
  <arm_group>
    <arm_group_label>albendazole at day 0, azithromycin at day 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>azithromycin at day 0, albendazole at day 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>albendazole at day 0, azithromycin at day 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>albendazole at day 7, azithromycin at day 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <arm_group_label>azithromycin at day 0, albendazole at day 7</arm_group_label>
    <arm_group_label>albendazole at day 0, azithromycin at day 0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <arm_group_label>albendazole at day 0, azithromycin at day 7</arm_group_label>
    <arm_group_label>albendazole at day 0, azithromycin at day 0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delayed treatment</intervention_name>
    <description>Albendazole+Azithromycin</description>
    <arm_group_label>Delayed treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all children 0 to 5 (up to 6th birthday)

        Exclusion Criteria:

          -  individuals with a macrolide allergy

          -  refusal of parent/guardian
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Keenan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>F.I. Proctor Foundation, University of California San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen Aiemjoy, MSc, PhD(C)</last_name>
    <phone>808.227.7633</phone>
    <email>kristen.aiemjoy@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dionna Fry, MPH</last_name>
    <phone>415.502.3192</phone>
    <email>dionna.fry@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Carter Center Ethiopia</name>
      <address>
        <city>Addis Ababa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2017</study_first_submitted>
  <study_first_submitted_qc>January 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2017</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Francis I. Proctor Foundation</investigator_affiliation>
    <investigator_full_name>Jeremy Keenan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>intestinal microbiome</keyword>
  <keyword>soil-transmitted helminths</keyword>
  <keyword>mass drug administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helminthiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

